2211.HK rises 35.04% to HK$5.01 on 27 Jan 2026 (Market Closed): top gainer insight
The 2211.HK stock led Hong Kong gains on 27 Jan 2026, rising 35.04% to HK$5.01 on heavy volume. Trading closed with 23,261,463 shares changing hands, against an average of 535,062, signalling a clear breakout on the HKSE. The move followed no single public earnings surprise, so we look at liquidity, technicals and sector context to explain the rally and what investors should watch next.
Price action and trading metrics for 2211.HK stock
Universal Health International Group Holding Limited (2211.HK) closed at HK$5.01, up HK$1.30 from the prior close of HK$3.71. Day range was HK$4.00–HK$5.15 and the stock traded 23,261,463 shares, a relative volume of 14.77, indicating speculative interest.
Average price over 50 days is HK$1.90 and over 200 days is HK$1.46, so the current price is well above trend averages. The intraday and multi‑period gap suggests momentum traders and new buyers pushed the move.
Fundamentals and valuation snapshot for 2211.HK stock
Universal Health (2211.HK) reports trailing EPS of ‑HK$0.36 and a TTM PE of ‑12.17, reflecting a loss. The market cap is HK$350,867,977 and book value per share is HK$3.96, giving a PB near 0.98.
Price to sales is 0.44 and operating margins are negative. The company shows low leverage with debt to equity 0.08, and a current ratio of 1.31, suggesting reasonable short‑term liquidity despite negative earnings.
Technical indicators and why 2211.HK stock popped
Momentum indicators flagged heavy activity: RSI at 17.59 was oversold pre‑rally, and relVolume spiked to 14.77 on the breakout. The 50‑day average of HK$1.90 vs price HK$5.01 made 2211.HK a clear technical target.
MACD and ADX (29.84) show a strong trending environment. Short covering and heavy retail flows are consistent with the volume surge and rapid price jump.
Meyka AI grade and model forecast for 2211.HK stock
Meyka AI rates 2211.HK with a score out of 100: 58.45/100, Grade C+, suggestion HOLD. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, analyst consensus and forecasts.
Meyka AI’s forecast model projects Yearly: HK$3.29 and 3‑year: HK$6.41. Versus the current HK$5.01, the yearly forecast implies ‑34.34% downside to the year estimate, while the 3‑year forecast implies +27.95% upside. Forecasts are model‑based projections and not guarantees.
Sector context and peers affecting 2211.HK stock
2211.HK operates in Healthcare on the HKSE within Medical‑Pharmaceuticals. The broader healthcare sector average PE is near 29.59, higher than Universal Health’s negative PE. Sector performance has been mixed, with established pharma and biotech names showing stronger profit metrics.
Compare peer listings and relative activity on investment platforms for context. See competitor comparisons on Investing.com for further detail source 1 and source 2.
Risks, catalysts and what to watch in 2211.HK stock
Key risks include continued negative EPS, low interest coverage (reported ‑97.48) and earnings dependence on regional distribution volumes. Regulatory action in China and supply chain disruptions add uncertainty.
Potential catalysts are stronger retail sales, margin improvement, or an acquisition announcement. Monitor volume, filings, and the next earnings announcement date of 25 Feb 2025 for any material updates. For company details use the Meyka stock page Meyka stock page.
Final Thoughts
Universal Health (2211.HK) emerged as a top gainer on 27 Jan 2026, rising 35.04% to HK$5.01 on heavy volume. The spike reflects technical buying, short covering and speculative flows rather than an immediate turnaround in fundamentals. Key metrics remain mixed: EPS ‑HK$0.36, PE ‑12.17, PB 0.98, and a market cap near HK$350,867,977. Meyka AI rates the stock 58.45/100 (C+, HOLD) and flags both upside and downside scenarios. Meyka AI’s forecast model projects 3‑year HK$6.41, implying about +27.95% from today, while the 1‑year model at HK$3.29 implies downside. Investors should balance the momentum trade with fundamentals, watch volume and filings, and treat forecasts as model projections, not guarantees. Meyka AI provides this as one data point in a broader analysis of the HKSE healthcare landscape.
FAQs
Why did 2211.HK stock jump today
The surge to HK$5.01 was driven by heavy volume and technical buying. Relative volume of 14.77 suggests short covering and retail inflows rather than a single public earnings surprise.
What are the main risks for 2211.HK stock
Main risks include negative EPS (‑HK$0.36), weak interest coverage, regulatory exposure in China, and reliance on distribution margins. Continued volatility is likely.
What price targets exist for 2211.HK stock
Meyka AI’s model projects Yearly HK$3.29 and 3‑year HK$6.41. These are model projections and not guarantees. Use them with other research before trading.
How does 2211.HK compare to healthcare peers
2211.HK trades at a negative PE while sector peers average PE near 29.59. The company has a low debt ratio but lower profitability than larger peers.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
